Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

When it comes to roles he's played over the course of his career, Matthew Lillard thinks that Scream villain Ghostface would be no match for another iconic character: Shaggy in Scooby-Doo.

When it comes to roles he's played over the course of his career, Matthew Lillard thinks that Scream villain Ghostface would be no match for another iconic character: Shaggy in Scooby-Doo. During a ...

The Milwaukee Bucks have hit a rough stretch of play. The Bucks have lost three games in a row, including an absolutely gut-wrenching loss to the Pacers on Tuesday. In that game, the Bucks lost by ...

Irish influencer and OnlyFans star Matthew Gilbert has been named in the latest list of tax defaulters after reaching settlements of more than €350,000 with the tax authority towards the end of ...

Damian Lillard is playing better this season than in his first year with the Milwaukee Bucks, averaging 25.5 points, 4.7 rebounds and 7.1 assists. However, Lillard has already missed 10 games this ...

Swarming bees, a story of sweet retribution, and a joyful, mandolin-playing Matthew McConaughey led “The Rivals of Amziah King” to a roaring standing ovation after its late night premiere at ...

Matthew McConaughey's new movie 'The Rivals of Amziah King' — his first live-action role since 2019 — premieres at SXSW on Monday, March 10 Amy E. Price/Getty Matthew McConaughey is back on ...

Novo announced results from a new weight loss drug that failed to meet expectations. Despite the results, the company is still in a strong position to continue leading the weight loss space.

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. Three months after missing that target in its first phase 3 CagriSema trial, the Danish drugmaker has fallen ...

Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...